Proprietary mRNA platform that achieves dramatically higher and more durable protein expression for next-generation therapeutics.
APEXm (Amplified and Prolonged Expression mRNA) is ParcelBio's core platform that uses proprietary RNA domains to recruit the cell's native stabilizing machinery, producing significantly higher and longer-lasting protein expression than conventional mRNA. The modular platform can encode any protein in any target cell type and is being deployed for in vivo CAR-T in autoimmune diseases, oncology, and therapeutic protein delivery. ParcelBio is backed by Breyer Capital, Y Combinator, and General Catalyst. APEXm is a product of ParcelBio.